Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | MC5R | P33032 | 1/20 | 0.68 |
| ▸ | MC3R | P41968 | 1/20 | 0.68 |
| ▸ | MC1R | Q01726 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | AHR | P35869 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385251 | 1.00 | HTR2A (1.00) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL2684408 | 0.98 | HTR2A (0.97) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| Water SCHEMBL27796022 | 0.97 | HTR2A (0.93) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| Cyanide SCHEMBL29233340 | 0.95 | HTR2A (0.90) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| SCHEMBL1248752 | 0.90 | HTR2A (0.81) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| SCHEMBL17232881 | 0.85 | MC5R (0.83) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| SCHEMBL27034106 | 0.85 | HTR2A (0.72) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| SCHEMBL7970552 | 0.84 | MC5R (0.81) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| SCHEMBL1972829 | 0.83 | HTR2A (1.00) | HTR2AHTR1AKDM4EALDH1A1HTT | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2AHTR1AKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1063 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4297723-B1 | MICRONEEDLE COMPOSITIONS AND METHODS OF DELIVERY USING THE SAME | BRIGHAM & WOMENS HOSPITAL INC (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| CN-120195298-A | Metabolic marker composition for discriminating tobacco grades, screening method and application | 哈尔滨脉图精准技术有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250129399-A1 | RECOMBINANT PRODUCTION OF PSILOCIN AND RELATED COMPOUNDS | NEUERA PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | claimed |
| CN-119614279-A | Energy-saving gear lubricating oil and preparation method thereof | 安徽中天石化股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-20240385183-A1 | METABOLIC AND MICROBIAL BIOMARKERS FOR DETECTION OF PANCREATICOBILIARY CANCERS | NORTHWESTERN UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-10 | — | — | US | claimed |
| WO-2004037801-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-20040002604-A1 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003050099-A1 | PHENYLALKYNES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | claimed |
| EP-0251938-B1 | STEREOSPECIFIC PROCESS FOR THE SYNTHESIS OF INDOLE DERIVATIVES | SANOFI (FR) | 1991-11-06 | — | — | EP | claimed |
| EP-0251938-A1 | Stereospecific process for the synthesis of indole derivatives | SANOFI (FR) | 1988-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | HTR2A 51/4885HTR1A 75/4885KDM4E 2587/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR1A 9/4885KDM4E 1355/4885 |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | HRH2, HNMT, HRH3 | HTR2A 338/4885HTR1A 713/4885KDM4E 1401/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | HTR2A 2610/4885HTR1A 2572/4885KDM4E 3063/4885 |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | HRH3, HRH2, HRH4 | HTR2A 24/4885HTR1A 17/4885KDM4E 1122/4885 |
| US-20040002604-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HTR2A 98/4885HTR1A 103/4885KDM4E 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.